Andrea Naaum, MD
Psychiatry · Fort Wayne, INNPI 1487071809
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 335 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,871 and has fallen 97.9% since, to $40 in 2025. Among psychiatry clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 335 payments — averaging $22.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$868
- AbbVie$838
- Johnson & Johnson$718
- Alkermes, Inc.$668
- Sunovion Pharmaceuticals Inc.$610
- plus $2K from 15 others
What the payments were for
- Food & beverage$7,49298%
- Education$1192%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 37 | $1,585 |
| Teva Pharmaceuticals USA, Inc. | 26 | $868 |
| AbbVie(2 entities) | 57 | $838 |
| Johnson & Johnson | 25 | $718 |
| Alkermes, Inc. | 24 | $668 |
| Sunovion Pharmaceuticals Inc. | 30 | $610 |
| Neurocrine Biosciences, Inc. | 23 | $600 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $446 |
| Lundbeck LLC | 51 | $401 |
| Corium, LLC | 6 | $186 |
| Vanda Pharmaceuticals Inc. | 6 | $129 |
| Indivior Inc. | 7 | $126 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $114 |
| Supernus Pharmaceuticals, Inc. | 5 | $92 |
| Biogen | 3 | $69 |
| E.r. Squibb & Sons, L.L.C. | 2 | $67 |
| Eisai Inc. | 2 | $27 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $25 |
| Noven Therapeutics, LLC | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Tris Pharma Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY MAINTENA$482
- REXULTI$364
- INVEGA SUSTENNA$332
- Austedo XR$249
- INGREZZA$246
- AUSTEDO$244
- INVEGA TRINZA$227
- VRAYLAR$125
- VIVITROL$125
- Azstarys$121
- CAPLYTA$121
How this compares
$7,611 in reported general payments places this provider in the 90th percentile of 514 psychiatry providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 75 | $255,451 |
| IngrezzaValbenazine Tosylate | 30 | $232,829 |
| Abilify MaintenaAripiprazole | 78 | $214,641 |
| VraylarCariprazine Hcl | 19 | $27,159 |
| TrintellixVortioxetine Hydrobromide | 40 | $25,729 |
| Divalproex Sodium ErDivalproex Sodium | 76 | $6,949 |
| Clozapine | 118 | $6,760 |
| Chlorpromazine Hcl | 33 | $6,037 |
| Haloperidol Decanoate | 68 | $4,346 |
| Ramelteon | 33 | $3,679 |
| Olanzapine | 85 | $3,508 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 42 | $3,074 |
| Ziprasidone Hcl | 43 | $2,892 |
| Duloxetine Hcl | 62 | $2,805 |
| Quetiapine Fumarate | 92 | $2,336 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $718 | $255,45175 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $600 | $232,82930 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $1,585 | $214,64178 claims |
| AbbVieVraylar | $838 | $27,15919 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $114 | $25,72940 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 514 psychiatry providers in Indiana.
Other psychiatry in Fort Wayne
- Larry LambertsonFort Wayne$208K
- Prevesh RustagiFort Wayne$64K
- Mahender SurakantiFort Wayne$13K
- Geeta BishtFort Wayne$11K
- Steven PaulCarmel$2.9M
- Jay FawverAngola$1.4M
- Suhayl NasrMichigan City$739K
- Christopher BojrabCarmel$713K
- Joseph FanelliMunster$443K
- Eric JaggersJeffersonville$260K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.